222 - Clinical and microbiological outcomes for Enterobacterales uropathogens in the Phase 3 ADAPT-PO Study of oral tebipenem pivoxil hydrobromide

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

Ian A. Critchley, PhD

Vice President, Head
Spero Therapeutics
Cambridge, Massachusetts, United States

PE

Paul B. Eckburg, MD

Consultant
Spero Therapeutics
Cambridge, Massachusetts, United States
LM

Lori A. Muir, B.Sc.

Director
Spero Therapeutics
Cambridge, Massachusetts, United States
AD

Aaron Dane, MSc

Director
Danestat Consulting Limited
Macclesfield, England, United Kingdom
GM

Gary E. Moore, PhD

Moore Computing Services
Moore Computing Services, Inc.
Little Rock, Arkansas, United States
DM

David Melnick, MD

Senior Scientific Advisor
Spero Therapeutics
Cambridge, Massachusetts, United States
Angela K. Talley, MD

SVP, Clinical Development
Spero Therapeutics
Cambridge, Massachusetts, United States